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The R‐CHOP combination is considered standard of care for patients with DLBCL \[[1](#onco12965-bib-0001){ref-type="ref"}\], although there is concern about increased toxicity in the elderly population \[[2](#onco12965-bib-0002){ref-type="ref"}\]. Older patients with DLBCL have been shown to have a worse outcome than corresponding younger patients on the same treatment regimen \[[3](#onco12965-bib-0003){ref-type="ref"}\]. A lower tolerance to treatment, comorbidities, and an inferior immunosurveillance have been analyzed and reviewed as important causes for the differences in outcome between young and older patients with DLBCL \[[2](#onco12965-bib-0002){ref-type="ref"}\]. For this reason, alternative effective treatment modalities with less toxicity are required in the elderly population.

Bendamustine is an alkylating agent that causes intra‐ and interstrand cross‐links between DNA bases \[[4](#onco12965-bib-0004){ref-type="ref"}\]. Studies of the combination of bendamustine and rituximab in elderly patients have demonstrated a complete response rate of approximately 50%, and the combination was associated with lower rates of grade ≥3 hematologic toxicities than R‐CHOP \[[5](#onco12965-bib-0005){ref-type="ref"}\], \[[6](#onco12965-bib-0006){ref-type="ref"}\], \[[7](#onco12965-bib-0007){ref-type="ref"}\].

Ofatumumab is fully human anti‐CD20 antibody, well tolerated by elderly patients, that induces B‐cell lysis primarily through complement‐dependent cytotoxicity and antibody‐dependent cell‐mediated cytotoxicity \[[8](#onco12965-bib-0008){ref-type="ref"}\]. The antibody recognizes a different epitope of the CD20 molecule than rituximab \[[9](#onco12965-bib-0009){ref-type="ref"}\], \[[10](#onco12965-bib-0010){ref-type="ref"}\].

In this study, we evaluated the safety and efficacy of ofatumumab plus bendamustine for the treatment of DLBCL in the elderly population. The drug combination is safe, but efficacy was modest. At 33.3% (Table [1](#onco12965-tbl-0001){ref-type="table"}), the complete response rate was lower than the historic CRRs of approximately 50% in elderly patients treated with bendamustine plus rituximab \[[5](#onco12965-bib-0005){ref-type="ref"}\], \[[6](#onco12965-bib-0006){ref-type="ref"}\], \[[7](#onco12965-bib-0007){ref-type="ref"}\]. However, it should be noted that the median PFS and median OS in this study, at 8.6 months and 12 months respectively, were generally consistent with those observed in similar populations treated with bendamustine plus rituximab \[[5](#onco12965-bib-0005){ref-type="ref"}\], \[[6](#onco12965-bib-0006){ref-type="ref"}\], \[[7](#onco12965-bib-0007){ref-type="ref"}\]. The poor response rate seen here may have been due, in part, to patient age and general health. The inclusion criteria for this study required patients to be ≥70 years old and also to be considered poor candidates for R‐CHOP therapy. Elderly patients unable to tolerate R‐CHOP treatment may still derive some benefit from this treatment regimen. Further studies are needed to better identify less toxic, but more efficacious, therapies for DLBCL for patients too frail to receive R‐CHOP.

###### Treatment response (*n* = 21)

![](onco12965-tbl-0001){#nlm-graphic-1}

Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression‐free survival; TTP, time to progression.
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DiseaseLymphoma -- non‐HodgkinsStage of Disease/TreatmentMetastatic/advancedPrior TherapyNoneType of Study -- 1Phase IIType of Study -- 2Single armPrimary EndpointComplete response rateSecondary EndpointProgression‐free survivalSecondary EndpointOverall response rateSecondary EndpointOverall survivalInvestigator\'s AnalysisLevel of activity did not meet planned endpoint

Drug Information {#onco12965-sec-0008}
================

Drug 1  **Generic/Working Name**Bendamustine **Trade Name**Treanda **Company Name**Cephalon, Inc. **Drug Type**Antineoplastic/cytotoxic **Drug Class**Alkylating agent **Dose**90 milligrams (mg) per squared meter (m^**2**^) **Route**IV **Schedule of Administration**Days 1 and 2 of cycles 1 through 6Drug 2  **Generic/Working Name**Ofatumumab **Trade Name**Arzerra **Company Name**GlaxoSmithKline **Drug Type**Antibody **Drug Class**CD20 **Dose**1000 milligrams (mg) per flat dose **Route**IV **Schedule of Administration**Days 1 and 8 during cycle 1 only and on day 1 of cycles 2 through 6

Patient Characteristics {#onco12965-sec-0009}
=======================

**Characteristic(*n* = 21), *n* (%)**Median age, years (range)83 (73--88)Sex Male9 (42.9) Female12 (57.1)Race  White20 (95.2) American Indian/Alaskan Native1 (4.8)Modified Ann Arbor stage at diagnosis  Stage III14 (66.7) Stage IV7 (33.3)Median B2‐microglobin (range)3 (0--7)B2‐microglobin normality  Abnormal18 (85.7) Normal3 (14.3)Cancer Types or Histologic SubtypesDLBCL, 21

Primary Assessment Method {#onco12965-sec-0010}
=========================

TitleComplete Response (CR)Number of patients screened21Number of patients enrolled21Number of patients evaluable for toxicity21Number of patients evaluated for efficacy21Evaluation methodInternational Working Group for Response CategoriesResponse Assessment CR*n* = 7 (33.3%)Response Assessment PR*n* = 12 (57.1%)Response Assessment SD*n* = 1 (4.8%)Response Assessment PD*n* = 1 (4.8%)Response Assessment Other*n* = 0 (0%)(Median) Duration Assessments PFS8.6 months, CI: 90%(Median) Duration Assessments TTP10.5 months, CI: 90%(Median) Duration Assessments OS12.0 months, CI: 90%

Adverse Events {#onco12965-sec-1010}
==============

imageJohn Wiley & Sons, Ltd.[^1]

Assessment, Analysis, and Discussion {#onco12965-sec-0011}
====================================

CompletionStudy completedInvestigator\'s AssessmentLevel of activity did not meet planned endpoint

 {#onco12965-sec-1011}

Over 50% of patients with diffuse large B‐cell lymphoma (DLBCL) are 65 years of age or older \[[5](#onco12965-bib-0005){ref-type="ref"}\], and older patients with DLBCL have been shown to have a worse outcome than younger patients \[[6](#onco12965-bib-0006){ref-type="ref"}\]. In this study, we evaluated the safety and efficacy of bendamustine plus the anti‐CD20 monoclonal antibody ofatumumab for the treatment of DLBCL in older patients who were not good candidates for rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) therapy. Treatment summary is shown in Table [2](#onco12965-tbl-0002){ref-type="table"}. The most common grade ≥3 AEs were thrombocytopenia (14%), neutropenia (10%), diarrhea (10%), vomiting (10%), and dehydration (10%; Table [3](#onco12965-tbl-0003){ref-type="table"}). The overall response rate was 90.5%, and the complete response (CR) rate was 33.3%. Median progression‐free survival (PFS) was 8.6 months (Fig. [1](#onco12965-fig-0001){ref-type="fig"}), median time to progression was 10.5 months (Fig. [2](#onco12965-fig-0002){ref-type="fig"}), and median overall survival was 12.0 months (Fig. [3](#onco12965-fig-0003){ref-type="fig"}). The study was closed early because of low accrual. This study demonstrated the safety of the bendamustine plus ofatumumab combination for the treatment of DLBCL in this patient population. However, with a CR rate of 33.3%, this drug combination showed modest efficacy compared with standard of care, but median survival was comparable to bendamustine plus rituximab.

The study was discontinued early because of low enrollment rates. The low CR rate for patients on this study regimen may have dampened enthusiasm for later patient enrollment. In addition, the common use of other treatment regimens such as rituximab plus bendamustine may have resulted in fewer patients entering the study. The combination of rituximab plus bendamustine treatment regimens has demonstrated some efficacy in older patients with DLBCL \[[5](#onco12965-bib-0005){ref-type="ref"}\], \[[6](#onco12965-bib-0006){ref-type="ref"}\], \[[7](#onco12965-bib-0007){ref-type="ref"}\], but there remains a critical need for safer and more effective therapies.

Although the efficacy of ofatumumab plus bendamustine as first‐line treatment for DLBCL in older patients was modest, elderly patients unable to tolerate R‐CHOP treatment may still derive some benefit from this treatment regimen. The drug combination was safe in the study population, and both PFS and overall survival were similar to those seen in patients treated with rituximab and bendamustine \[[5](#onco12965-bib-0005){ref-type="ref"}\], \[[6](#onco12965-bib-0006){ref-type="ref"}\], \[[7](#onco12965-bib-0007){ref-type="ref"}\]. There may also be some use for ofatumumab in treating rituximab‐refractory patients. Ofatumumab targets a different epitope on the CD20 molecule \[[9](#onco12965-bib-0009){ref-type="ref"}\], \[[10](#onco12965-bib-0010){ref-type="ref"}\] than rituximab, and the drug has been shown to be active in patients with rituximab‐refractory follicular lymphoma \[[11](#onco12965-bib-0011){ref-type="ref"}\]. Similarly, it may have efficacy in the treatment of rituximab‐refractory DLBCL.

Figures and Tables {#onco12965-sec-3013}
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###### Treatment summary (*n* = 21)

![](onco12965-tbl-0003){#nlm-graphic-5}

One patient with poor posthospitalization status, including G3/2 unrelated diarrhea; one patient, both physician/patient decision (due to valvular heart disease).

Causes of death: One patient, treatment‐related sepsis and bowel necrosis; one patient, cause unknown, unrelated.

Abbreviations: AE, adverse event; EOS, end of study.

###### Toxicities grade ≥3 (*n* = 21)

![](onco12965-tbl-0004){#nlm-graphic-7}

All hematologic toxicities reported, regardless of causality.

Only related nonhematologic toxicities are reported.

![Progression‐free survival (*n* = 21).\
Abbreviations: CI, confidence interval; PFS, progression‐free survival.](onco12965-fig-0001){#onco12965-fig-0001}

![Time to progression (*n* = 21).\
Abbreviations: CI, confidence interval; TTP, time to progression.](onco12965-fig-0002){#onco12965-fig-0002}

![Overall survival (*n* = 21).\
Abbreviations: CI, confidence interval; OS, overall survival.](onco12965-fig-0003){#onco12965-fig-0003}
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[^1]: Abbreviations: NC/NA, no change from baseline/no adverse event.
